target downgrad unit state go sg websit
mix result smart strateg refocu toward innov
report slightli lower expect sale due declin
legaci portfolio compani manag report better expect
ep thank lower cog cut guidanc reflect jv
gsk compani made strateg move off-pat product upjohn
divis refocu innov cut tp reflect
perform new guidanc
mix perform sale legaci portfolio expect partial
off-set newer product pfizer sale grew constant exchang rate cer
upsid tp
nc chang
came consensu howev adjust ep
beat sge con due mainli lower cog oper margin reach
yoy pharma sale new product cancer ibranc xalkori
beat sale prevnar vaccin enbrel old gener drug immune-
inflamm miss consensu expect respect
legaci product includ lipitor norvasc viagra overal legaci portfolio
total group sale short consensu expect downgrad
guidanc reflect gsk consum jv recent acquisit array biopharma
new guidanc sale vs earlier non-gaap ep
vs adjust estim accordingli
move refocu innov smart accord manag
upjohn divis off-pat product sale combin via spin-
split accord plan sharehold new entiti
assum share new compani share upjohn issu
debt retain proce expect new compani total
revenu ebitda margin see cost synergi
newco sale line averag sector
hold reiter attract new product cancer inflamm
think enough re-energ group top line low single-digit growth
vs sector group stand-alone basi trade line peer
price-to-earnings slower expect growth ep compound-annual-growth-rate vs
peer
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
simplifi main product divis
sell inform administr
compani data sg cross asset research/equ consensu estim streetaccount
mylan/upjohn combin smart move refocu innov
new compani form revers morri transact expect
tax-fre sharehold requir approv sharehold
sharehold deal slate close upon complet
sharehold would hold combin compani sharehold would hold
remain combin compani incorpor delawar three global
centr pittsburgh pennsylvania shanghai china upjohn current global headquart
compani expect newco total debt
upjohn fund pre-clos cash payment
newco manag includ robert couri execut chairman michael goettler
ceo rajiv malik presid combin compani elect director includ
eight appointe three appointe combin board fulli
declassifi
newco pro forma outlook includ expect revenu adjust ebitda
annual free cash flow manag expect
newco revenu come north america europ asia emerg
market regard qualiti revenu like come gener
us gener market rest prescript brand over-the-counter medicin
biosimilar dividend receiv sharehold remain flat new
organis assum continu ownership new gener entiti
revenu ebitda contribut bn
expect combin compani see roughli annual cost synergi
line sector standard combin sale gross leverag less
ebitda
found strateg move quit posit long term remain focuss
innov keep busi grow proce may use acquir
products/compani boost pipelin
main topic form confer call manag
updat upjohn busi oper revenu upjohn fell main driver
china declin driven primarili volume-bas procur
reform implement march reform unfavour impact lipitor
norvasc oper revenu upjohn china full year guid grow
low mid-single-digit pace
innov busi china exclud upjohn busi extrem healthi accord
manag grow quarter compani expect growth remain
unchang acceler maintain innov busi capabl upjohn
capabl alreadi segreg strong research organis china
compani plan maintain enhanc also plan introduc new product
next year segment
propos senat drug price legisl compani support bill
current form manag view provis could support
institut out-of-pocket cap patient improv incent biosimilar
bill gener save healthcar system distribut benefit patient
fundament issu pharma industri compani note
unanim support introduc comprehens rebat reform bill manag
felt earli comment potenti
updat xeljanz prescrib inform us remain confid benefit risk
profil drug studi clinic trial prescrib
adult patient world-wide howev stage expect impact
prescrib enterpris level impact off-set strength part
busi reiter view sale potenti though product like
impact grow competit potent better toler product
tp cut vs
part
averag pharma premium innov
vaccin consum discount matur portfolio
adjust estim reflect new guidanc downgrad tp accordingli
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jul cet
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
averag sotp averag ev/ebita us pharma multipl appli estim ebita subdivis
premium innov product premium vaccin consum discount matur portfolio dcf
main risk gener competit lyrica neuropath pain biosimilar enbrel inflamm presenc signific tail
product total sale upsid risk stronger growth ibranc eliqui togeth group sale late-stag pipelin cancer
pain
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
equiti rate dispers relationship
updat
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
sg act joint bookrunn bond issu
